Table 1 Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients
A. Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients of Sun Yat-sen University | ||||||
|---|---|---|---|---|---|---|
Characteristics | miR-320a (%) | Integrin β3 (%) | ||||
No. of low expression | No. of high expression | P | No. of low expression | No. of high expression | P | |
Sex | 0.905 | 0.097 | ||||
Male | 83 (61.9) | 51 (38.1) | 45 (33.6) | 89 (66.4) | ||
Female | 106 (63.1) | 62 (36.9) | 73 (43.5) | 95 (56.5) | ||
Age | 0.153 | 0.814 | ||||
<50 | 82 (58.2) | 59 (41.8) | 54 (38.3) | 87 (61.7) | ||
≥50 | 107 (66.5) | 54 (33.5) | 64 (39.8) | 97 (60.2) | ||
Tumor Size | 0.801 | 0.319 | ||||
T1-2 | 125 (61.9) | 77 (38.1) | 83 (41.1) | 119 (58.9) | ||
T3-4 | 64 (64.0) | 36 (36.0) | 35 (35.0) | 65 (65.0) | ||
Node metastasis | 0.029 | 0.032 | ||||
N0 | 154 (59.9) | 103 (40.1) | 107 (41.6) | 150 (58.4) | ||
N1 | 35 (77.8) | 10 (22.2) | 11 (24.4) | 34 (75.6) | ||
TNM stage | 0.074 | 0.044 | ||||
I-II | 95 (57.9) | 69 (42.1) | 73 (44.5) | 91 (55.5) | ||
III-IV | 94 (68.1) | 44 (31.9) | 45 (32.6) | 93 (67.4) | ||
Distant Metastasis | <0.001 | 0.001 | ||||
No | 90 (52.3) | 82 (47.7) | 81 (47.1) | 91 (52.9) | ||
Yes | 99 (76.2) | 31 (23.8) | 37 (28.5) | 93 (71.5) | ||
Status | 0.002 | 0.009 | ||||
Survival | 84 (54.2) | 71 (45.8) | 72(46.5) | 83 (53.5) | ||
Death | 105 (71.4) | 42 (28.6) | 46(31.3) | 101 (68.7) | ||
B. Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients of Central South University | ||||||
Sex | 0.496 | 0.865 | ||||
Male | 53 (66.2) | 27 (33.8) | 29 (36.2) | 51 (63.8) | ||
Female | 41 (60.3) | 27 (39.7) | 26 (38.2) | 42 (61.8) | ||
Age | 0.170 | 0.609 | ||||
<50 | 47 (58.0) | 34 (42.0) | 32 (39.5) | 49 (60.5) | ||
≥50 | 47 (70.1) | 20 (29.9) | 23 (34.3) | 44 (65.7) | ||
Tumor Size | 0.601 | 0.861 | ||||
T1-2 | 60 (65.2) | 32 (34.8) | 35 (38.0) | 57 (62.0) | ||
T3-4 | 34 (60.7) | 22 (39.3) | 20 (35.7) | 36 (64.3) | ||
Node metastasis | 0.811 | 0.469 | ||||
N0 | 80 (63.0) | 47 (37.0) | 49 (38.6) | 78 (61.4) | ||
N1-N2 | 14 (66.7) | 7 (33.3) | 6 (28.6) | 15 (71.4) | ||
TNM stage | 0.392 | 0.608 | ||||
I-II | 56 (66.7) | 28 (33.3) | 33 (39.3) | 51 (60.7) | ||
III-IV | 38 (59.4) | 26 (40.6) | 22 (34.4) | 42 (65.6) | ||
Distant Metastasis | 0.001 | 0.004 | ||||
No | 42 (51.2) | 40 (48.8) | 39 (47.6) | 43 (52.4) | ||
Yes | 52 (78.8) | 14 (21.2) | 16 (24.2) | 50 (75.8) | ||
Status | 0.004 | 0.017 | ||||
Survival | 37 (51.4) | 35 (48.6) | 34 (47.2) | 38 (52.8) | ||
Death | 57 (75.0) | 19 (25.0) | 21 (27.6) | 55 (72.4) | ||